Articles tagged with Drug Discovery
Researchers at the University of Cape Town have identified a critical molecular switch that drives the formation of cancer-associated antigens. By understanding how enzymes relocate within a cell, they have uncovered key mechanisms for tumorigenesis.
Researchers at Gladstone Institutes identified hundreds of human genes influencing HIV infection and two potent antiviral proteins, PI16 and PPID. These proteins block HIV's entry into T cells or limit its ability to replicate within the cell.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
Researchers Dr Íris Luz Batalha and Dr Maria Shchepinova from the University of Bath have been awarded funding to test new ideas in tackling global health challenges. They will develop precision-targeted therapies for antimicrobial resistance and investigate why treatments for Type 2 diabetes don't work for everyone.
Four Ontario-based research teams are receiving funding to develop next-generation cancer therapies with improved efficacy and reduced side effects. The projects focus on breast and ovarian cancers, a hard-to-treat form of leukemia, and a 'master regulator' protein involved in many different cancers.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
The VCU Massey Comprehensive Cancer Center has completed the inaugural funding cycle of its collaborative drug discovery program with the Sanford Burnham Prebys Medical Discovery Institute. Two projects have received $50,000 each to advance innovative cancer drug discovery efforts.
Gladstone Institutes investigator Ryan Corces receives $750,000 to investigate unknown genetic variants contributing to Alzheimer's disease. He aims to identify new drivers and therapeutic targets using artificial intelligence and CRISPR tools.
Scientists have found that the APOE4 gene variant causes hyperactivity in two regions of the hippocampus, an important memory center of the brain, even before middle age. In mice with the APOE4 gene, reducing Nell2 levels reverses neuronal changes and improves cognitive function.
A hormone called FGF21 reverses obesity in mice by signaling to the hindbrain, a region targeted by GLP-1 drugs. This finding provides insight into the naturally occurring hormone's benefits for weight loss and MASH treatment.
Researchers from Kobe University have designed a small mirror protein that disables amyloid-beta, a causal factor of Alzheimer's disease. The approach uses the principle of 'chirality' to bind to the protein, inhibiting its aggregation and potential for brain cell damage.
A team from SickKids discovered a therapeutic target in fat tissue that improves cellular function and reduces inflammation. Low-dose homoharringtonine treatment selectively eliminates senescent cells, improving metabolic problems and preserving lean mass.
The new joint department combines expertise in medical devices, neuroengineering, imaging science, and more to advance biomedical research and translate discoveries into meaningful health advances. The partnership aims to accelerate the translation of discoveries into improvements in human health.
A new model of brain wiring could shorten the path to developing medicines for multiple sclerosis and other degenerative brain diseases. The model, made of a water-filled gel, replicates the physical properties of human axons and has been successfully grown from human cells in the laboratory.
The International Society for Stem Cell Research has named Stem Cell Reports as the official conference journal for the Latest Advances in Stem Cell-Based Disease Modelling and Drug Screening meeting. The journal will focus on high-impact research spanning basic discovery to clinical translation in stem cell science.
The latest SLAS Technology volume showcases how AI, automation, and portable technologies are transforming drug discovery and diagnostics. This advancement enables the development of innovative therapeutic solutions and improved patient care.
The latest volume of SLAS Discovery highlights advances in 3D cell culture and novel technologies for drug discovery. Small molecule cytokine antagonists and a versatile ELISA for PPI inhibitor screening are among the key findings.
This issue highlights advancements in drug discovery, synthetic biology, and laboratory digitalization. SLAS Technology emphasizes scientific and technical advances that enable improved biomedical research and development.
A team of researchers at MSU used machine learning to predict how chemicals will influence gene expression, leading to the discovery of promising compounds for the treatment of liver cancer and a chronic lung disease. The study results from years of interdisciplinary work across multiple disciplines and institutes.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Jeonbuk National University researchers have developed DDINet, a lightweight and scalable model that can accurately predict drug-drug interactions for new, unseen drugs. This approach avoids overfitting to training data and is designed to handle binary and multi-classification tasks.
Researchers developed a machine-learning system that predicts how molecules form, cutting lab work time from months to days and reducing costs. The system uses asymmetric cross-coupling reactions to build complex compounds and can be applied across fields, deepening our understanding of chemistry.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Researchers from MedUni Vienna have developed a new approach to drug discovery by targeting intracellular signalling proteins, such as β-arrestins, to control disease-relevant signalling pathways. This approach holds promise for personalized therapies, particularly for the treatment of neurological diseases.
Researchers at Goethe University are developing non-hormonal contraceptives to address declining pill use and side effects. The PREVENT project aims to create safe and effective alternatives, focusing on small molecules that block proteins in sperm or egg cells.
Researchers have developed a bacterial system to create millions of potential drug molecules that can target difficult-to-treat cancers. The approach combines chemical peptide stabilisation with the TBS assay to screen for effective peptides, which can then be tested in more complex tissue models and animal studies.
A new study finds that a novel GLP-1 receptor agonist, Exendin-4-Phe (Ex-Phe-1), preserves glycemic control while reducing malaise and vomiting behaviors in preclinical models. The compound uses biased agonism to selectively activate certain signaling pathways, achieving desired effects without triggering others.
Researchers at Osaka Metropolitan University found that targeting the glutamine transporter ASCT2 can suppress cell growth and induce apoptosis in synovial sarcoma cells. This study suggests a new approach for treating this aggressive malignant tumor by cutting off its nutrient supply.
Researchers developed a novel method to immobilize proteins onto magnetic microbeads, allowing precise measurement of binding strength and efficient selection of target peptides. The technique achieved a 10,000-fold concentration in a single sorting step, significantly enhancing the efficiency of drug discovery research.
Researchers at Sultan Qaboos University have identified three novel antimicrobial peptides from dromedary camels that effectively target multidrug-resistant bacteria. The peptides, CdPG-3 and CdCATH, demonstrate strong antibacterial activity across Gram-positive and Gram-negative bacteria.
Researchers developed a free-to-use software tool, PSBench, to verify the accuracy of artificial intelligence-based protein structure predictions. The database includes 1.4 million annotated protein models, verified by experts, and provides reliable information for building more accurate AI systems.
MIT researchers used a large language model to optimize the genetic sequences of proteins manufactured by yeast, reducing production costs. The new model predicted which codons would work best for manufacturing six different proteins, including human growth hormone and a monoclonal antibody, with successful results.
Researchers isolated native SOD1 monomers using coordination cages, revealing the dimer interface and enabling targeted ligand binding. This approach provides a promising new strategy for finding drugs that inhibit disease-causing protein aggregation.
The Global Exposome Forum is a global initiative that aims to understand the complex interplay between biological, chemical, and environmental exposures and human health. The project has partnered with national governments, scientific institutions, and large membership-led organizations to advance exposomics science.
The MIT research team has designed a new type of tissue model that accurately replicates the physiology of the liver, including blood vessels and immune cells. The model was used to study metabolic dysfunction-associated steatotic liver disease (MASLD) and showed promising results in identifying potential treatments.
A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer, a deadly form of breast cancer lacking targeted therapies. The researchers identified dsRNA-binding proteins, specifically PACT, which suppress another protein called RNA-activated protein kinase (PKR).
The article highlights Insilico Medicine's exclusive contributions to two chapters in the latest AI for Drug Discovery Volume, showcasing its expertise in real-life application of AI in early drug target-related tasks. The company's roadmap to 2030 using Quantum Machine Learning (QML) algorithms is also presented, with successful case ...
Researchers from Korea University report a breakthrough in reviving an abandoned depression drug target by redesigning the molecular structure of neurokinin-1 receptor antagonists. New compounds exhibiting antidepressant-like effects have been identified, reducing depressive-like behavior and brain inflammation in mice.
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
Southwest Research Institute has upgraded its nuclear magnetic resonance (NMR) laboratory to provide robust chemical analysis of organic compounds used in drug discovery and development. The new facility enables rapid and cost-effective analysis using qNMR, which can be more efficient than HPLC for certain applications.
Researchers at University Hospitals and Case Western Reserve University have discovered a novel enzyme, SCoR2, that removes nitric oxide from proteins controlling fat build-up. Inhibition of this enzyme prevents weight gain and liver injury in mouse models, also lowering bad cholesterol.
Researchers from Tokyo University of Science developed an efficient strategy to synthesize PROTACs using a three-step click chemistry method. This approach rapidly assembles functional molecules, enabling the easy introduction of ligand components and probe functionalities.
In a new study, Northwestern scientists identified a previously unknown toxic sub-species of amyloid beta oligomers that drive brain changes in Alzheimer's disease. NU-9 decreased this toxin and reduced damage in a mouse model, suggesting it could prevent or delay the cascade of toxic events that destroy neurons.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
A SickKids-led study reveals how bile acids can bind to block C. diff's most dangerous toxin, leading to the development of a new compound that neutralizes the toxin directly in the gut. This approach preserves gut health and targets the toxin with precision, offering hope for safer treatments.
Researchers developed a novel magnetic biosensing technique using polydopamine-coated magnetoliposomes to monitor lectin-glycan binding. The technique provides insight into the dynamics of sugar-protein interactions and holds promise for medical diagnostics, glycoscience research, and drug discovery.
Intellicule will utilize state-of-the-art deep-learning techniques to expand structural modeling and analysis for cryo-EM data. The company aims to overcome current limitations in biomolecular modeling, enabling the detection of atoms in low-resolution images.
The Jackson Laboratory's CARDIOVERSE project uses AI, stem cells, and genetic variation to predict drug safety before human trials. The initiative aims to reduce cardiotoxicity and improve patient stratification in clinical trials.
Researchers at Martin Luther University Halle-Wittenberg have developed a promising new substance that inhibits the ability of tuberculosis bacteria to produce energy and causes them to die. The compound, PRP020, targets the pathogen's ATP synthase but attacks a different site than existing drugs like bedaquiline.
Insilico Medicine will demonstrate how generative AI is accelerating therapeutic discovery, improving drug efficacy, and advancing personalized medicine. The company's pharma superintelligence platform aims to tackle challenging problems in modern science and medicine.
Biomedical researchers recommend diversifying funding sources, pursuing earlier licensing and commercialization, and fostering international collaborations. The US drug discovery landscape is at risk due to federal funding cuts, and alternative approaches are needed to ensure continued progress.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
Researchers identified TCF/LEF proteins as key regulators of the canonical Wnt pathway, which governs transcription in cancer and fibrotic diseases. The study reveals potential therapeutic targets for treating diverse diseases while avoiding toxicity associated with upstream Wnt inhibition.
Researchers found that selective enrichment of adhesion proteins like fibronectin and vitronectin maximizes optimal cell adhesion on plastic surfaces. The optimal UVO treatment time creates a mix of hydrophilic and hydrophobic regions, promoting attachment protein replacement and secure cell binding.
Researchers discover tiny antibody-like proteins from camels and llamas that can treat brain disorders like schizophrenia and Alzheimer’s disease with fewer side effects. The nanobodies are smaller than conventional antibodies, making them easier to produce and purify.
A new broad-spectrum antivenom developed by DTU researchers covers 17 African snake species and provides better protection against tissue damage, with a lower risk of immune reactions. The antivenom has shown impressive results in laboratory studies and could revolutionize the treatment of venomous snakebites in Africa.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
Researchers from The University of Osaka and The University of Tokyo have developed a novel technology that visualizes specific molecules inside living cells using light. The new photo-responsive alkyne tag enables precise visualization without disrupting molecular dynamics.